Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
This leukemia paper reports laboratory, mouse and limited human-sample findings. The primary-sample combination result at 48 hours does not improve apoptosis beyond steroid alone; longer-culture observations use two selected specimens. Mouse survival findings require qualification for unequal toxicity censoring. It does not establish human combination-treatment efficacy. Nolan is credited with resources and clinical data alongside a coauthor, without a named funding award or government/UAP approach in this article.
Partial specialist supplied XML; method section and apparatus unreviewed